{"title":"Successful Treatment of Facial Pseudolymphoma With Intravenous Rituximab: A Case Report","authors":"Elham Behrangi, Nastaran Khodakarim, Shila Amiri, Seyyedeh Tahereh Rahimi, Neda Safarzadeh, Alireza Jafarzadeh","doi":"10.1002/ccr3.71101","DOIUrl":null,"url":null,"abstract":"<p>Intravenous rituximab demonstrated significant efficacy in treating a case of refractory cutaneous pseudolymphoma that failed multiple conventional therapies, including corticosteroids, hydroxychloroquine, methotrexate, and biologics. The patient, a 42-year-old man, initially developed erythematous, nodular lesions on the face following dental implant surgery, which later spread and persisted despite various immunosuppressive and anti-inflammatory treatments. Histopathological and immunohistochemical analysis confirmed B-cell pseudolymphoma. Intravenous rituximab (500 mg weekly for 4 weeks, followed by maintenance doses) led to substantial lesion regression, with no recurrence observed after 1 year of follow-up. This case underscores the therapeutic potential of rituximab for treatment-resistant pseudolymphoma and highlights the need for further research into optimal treatment protocols for this rare condition.</p>","PeriodicalId":10327,"journal":{"name":"Clinical Case Reports","volume":"13 10","pages":""},"PeriodicalIF":0.6000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12485290/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ccr3.71101","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Intravenous rituximab demonstrated significant efficacy in treating a case of refractory cutaneous pseudolymphoma that failed multiple conventional therapies, including corticosteroids, hydroxychloroquine, methotrexate, and biologics. The patient, a 42-year-old man, initially developed erythematous, nodular lesions on the face following dental implant surgery, which later spread and persisted despite various immunosuppressive and anti-inflammatory treatments. Histopathological and immunohistochemical analysis confirmed B-cell pseudolymphoma. Intravenous rituximab (500 mg weekly for 4 weeks, followed by maintenance doses) led to substantial lesion regression, with no recurrence observed after 1 year of follow-up. This case underscores the therapeutic potential of rituximab for treatment-resistant pseudolymphoma and highlights the need for further research into optimal treatment protocols for this rare condition.
期刊介绍：
Clinical Case Reports is different from other case report journals. Our aim is to directly improve global health and increase clinical understanding using case reports to convey important best practice information. We welcome case reports from all areas of Medicine, Nursing, Dentistry, and Veterinary Science and may include: -Any clinical case or procedure which illustrates an important best practice teaching message -Any clinical case or procedure which illustrates the appropriate use of an important clinical guideline or systematic review. As well as: -The management of novel or very uncommon diseases -A common disease presenting in an uncommon way -An uncommon disease masquerading as something more common -Cases which expand understanding of disease pathogenesis -Cases where the teaching point is based on an error -Cases which allow us to re-think established medical lore -Unreported adverse effects of interventions (drug, procedural, or other).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
